Drug Trial Radar · NCT07247188
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Jan 7, 2027
Study completion Jan 7, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.
Conditions
- Sickle Cell Disease
Interventions
PCV21Biological
Investigational pneumococcal conjugate vaccine
20vPCVBiological
20-valent pneumococcal conjugate vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting immediate adverse events (AEs)Time frame: Within 30 minutes post-vaccination
- Number of participants reporting solicited injection site and solicited systemic reactionsTime frame: Up to Day 7 post-vaccination
- Number of participants reporting unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs after injection of a pneumococcal vaccineTime frame: Within 30 days post-vaccination
- Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From day 0 to day 181
- Number of participants with serotype-specific immunoglobulin G (IgG) concentrations for all serotypes included in PCV21Time frame: On day 30 post-vaccination
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Site # 8400006
Atlanta, Georgia · Recruiting
Site # 8400002
Atlanta, Georgia · Recruiting
Site # 8400003
Omaha, Nebraska · Recruiting
Site # 8400001
New Brunswick, New Jersey · Recruiting
Site # 8400004
Houston, Texas · Recruiting
Site # 2140001
Santo Domingo, Dominican Republic · Recruiting
Site # 2140003
Santo Domingo, Dominican Republic · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.